Peptide Atlas · Peptide

Relamorelin

Relamorelin (RM-131) is a selective ghrelin receptor agonist; in a 12-week phase 2B study in 393 people with diabetic gastroparesis, vomiting frequency fell 75% from baseline, but not significantly more than on placebo.

emerging

provisional
PubChem 44251769
2 citations
0 discussions
0 followers
BIM-28131
RM-131
pentapeptide ghrelin agonist

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Relamorelin increased antral contractions in healthy volunteers standing
- resolved
Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.
Nelson AD, Camilleri M, Acosta A, Busciglio I, Linker Nord S, Boldingh A, Rhoten D, Ryks M, Burton D
pmid 27283792
- emerging
  Claim: Relamorelin in diabetic gastroparesis (phase 2B): vomiting reduction not different from placebo standing
- resolved
Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT
pmid 28760384

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.